1. Label-free affinity screening, design and synthesis of inhibitors targeting the Mycobacterium tuberculosis L-alanine dehydrogenase
- Author
-
Kim, Heung-Bok, Bacik, John-Paul, Wu, Ruilian, Jha, Ramesh K, Hebron, Michaeline, Triandafillou, Catherine, McCown, Joseph E, Baek, Nam-In, Kim, Jeong Han, Kim, Young Jae, Goulding, Celia W, Strauss, Charlie EM, Schmidt, Jurgen G, Shetye, Gauri S, Ryoo, Sungweon, Jo, Eun-Kyeong, Jeon, Young Ho, Hung, Li-Wei, Terwilliger, Thomas C, and Kim, Chang-Yub
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Medicinal and Biomolecular Chemistry ,Chemical Sciences ,Built Environment and Design ,Design ,Prevention ,Infectious Diseases ,Rare Diseases ,Biodefense ,Orphan Drug ,Antimicrobial Resistance ,Tuberculosis ,Vaccine Related ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Alanine Dehydrogenase ,Mycobacterium tuberculosis ,Nucleosides ,Enzyme Inhibitors ,Drug Discovery ,General Science & Technology - Abstract
The ability of Mycobacterium tuberculosis (Mtb) to persist in its host may enable an evolutionary advantage for drug resistant variants to emerge. A potential strategy to prevent persistence and gain drug efficacy is to directly target the activity of enzymes that are crucial for persistence. We present a method for expedited discovery and structure-based design of lead compounds by targeting the hypoxia-associated enzyme L-alanine dehydrogenase (AlaDH). Biochemical and structural analyses of AlaDH confirmed binding of nucleoside derivatives and showed a site adjacent to the nucleoside binding pocket that can confer specificity to putative inhibitors. Using a combination of dye-ligand affinity chromatography, enzyme kinetics and protein crystallographic studies, we show the development and validation of drug prototypes. Crystal structures of AlaDH-inhibitor complexes with variations at the N6 position of the adenyl-moiety of the inhibitor provide insight into the molecular basis for the specificity of these compounds. We describe a drug-designing pipeline that aims to block Mtb to proliferate upon re-oxygenation by specifically blocking NAD accessibility to AlaDH. The collective approach to drug discovery was further evaluated through in silico analyses providing additional insight into an efficient drug development strategy that can be further assessed with the incorporation of in vivo studies.
- Published
- 2022